Developer docs
API playgroundTry for free, no card

Search company profiles

Strand Life Sciences

Full company profile

uuid0000hly

Namestring
Strand Life Sciences
Legal namestring
Strand Life Sciences
Websiteurl
strandls.com
Company typeenum
Private
Founded yearint
2000
Descriptiontext

Strand Life Sciences is a Bangalore-based, multi-omics solutions provider founded in 2000, operating as a subsidiary of Reliance Industries Limited. The company delivers an integrated platform spanning genomics, proteomics, transcriptomics, and spatial transcriptomics, with a portfolio of proprietary products including StrandNGS (NGS analysis software), PQRS (polygenic risk scoring), the scRNA Portal (single-cell RNA curation), and the StrandOmics clinical pipeline. Its technology stack combines AI-assisted variant interpretation, agentic AI for biomedical data curation, and a TileDB-integrated data architecture, supported by a CAP-accredited laboratory in India, HIPAA-compliant operations, and ISO 27001 certification.

Strand serves a hybrid customer base: global pharmaceutical and biotechnology enterprises seeking integrated multi-omics discovery, translational research, and biomarker validation programs (especially across India, South Asia, and West Asia); molecular diagnostics companies and US diagnostic/device firms requiring AI-driven somatic and germline variant interpretation, oncology panel reporting, and regulatory-compliant software; and, increasingly, the Indian healthcare system through affordable cancer screening and rare disease diagnostics. Strategic relationships include SOPHiA GENETICS (AI integration), Olink (high-throughput proteomics), TileDB (data infrastructure), and a tri-partite cancer biomarker testing program with Servier India and MedGenome.

The business model is predominantly professional services and B2B enterprise sales, with revenue generated from pharma biomarker discovery engagements, CAP-accredited lab services, software development for FDA/HIPAA-compliant omics platforms, and partnership-driven subsidized testing in India. Distribution leverages direct enterprise sales for global clients and the Reliance distribution network for consumer diagnostics in India, with a long-term strategic objective of reducing genomic test pricing to sub-Rs 1,000 to drive mass adoption similar to the Jio telecom disruption model.

Short descriptiontext

Strand Life Sciences is a Bangalore-based, Reliance Industries-backed multi-omics company providing AI-driven genomics, proteomics, and clinical diagnostics software and lab services to global pharmaceutical firms, US diagnostic companies, and the Indian healthcare system, with a strategic push toward affordable consumer genomic testing.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
501–1,000
akta.pro rankint
HeadquartersBangalore, India
HQ citystring
Bangalore
HQ countrystring
India
HQ regionstring
Asia
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
multi-omics bioinformatics, clinical genomic diagnostics, pharma biomarker discovery, NGS data analysis, AI variant interpretation
Industry4 codes
PRIMARYHLAGANAI
Bioinformatics, Multi-Omics Data Analysis & Interpretation Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
SECONDARYHLAGAJAD
Bioinformatics & Multi-omics Analysis Software
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAGANAE
Transcriptomics & Gene Expression Profiling Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
SECONDARYHLAAAMAJ
Genomic & Multi-Omic Biomarkers (NGS panels, transcriptomics, proteomics, metabolomics)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
NAICS code3 codes
  • Scientific Research and Development Services5417
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Software Publishers5132
SIC code2 codes
  • Services-Commercial Physical & Biological Research8731
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Genomic Diagnostics & Bioinformatics Services
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model4 records
1Genomic Diagnostics Services
TypeProfessional Services
Description

B2B services providing NGS and PCR diagnostics, biomarker testing, and clinical reporting to pharmaceutical companies, biotechnology organisations, and diagnostic laboratories.

expresshealthcare.in
2Pharma and Biomarker Discovery
TypeProfessional Services
Description

Clinical data and bioinformatics solutions for pharmaceutical companies for target discovery, translational research, and clinical research.

strandls.com
3Software Development Services
TypeProfessional Services
Description

Omics software development for managing and analyzing data, including HIPAA- and FDA-compliant software for medical devices and genomics tests.

strandls.com
4CAP-Accredited Laboratory Services
TypeProfessional Services
Description

Data generation services including single-cell, spatial transcriptomics and genomics from clinical samples in India-based CAP accredited laboratory.

strandls.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales
Pricing details1 tier
1CancerSpot cancer screening tests targeted at Rs 999
ModelUnit PricingBilling cadenceOne time/ perpetual license
Notes

Reliance-backed initiative aims to reduce gene sequencing costs to sub-Rs 1,000 tests, similar to Jio telecom disruption model.

economictimes.indiatimes.com
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 4 records shown
1scRNA Portal
Description

Portal for single-cell RNA curation and analysis

strandls.com
+3 more records
Core offering1 text field

Strand Life Sciences provides integrated multi-omics solutions combining genomics, proteomics, transcriptomics, and spatial transcriptomics with AI-driven bioinformatics for pharmaceutical, biotechnology, and diagnostic customers. Core offerings include Pharma and Biomarker Discovery, High-Throughput Proteomics using the Olink Explore HT platform, NGS and PCR clinical diagnostics, software application development, and compliance services. Standalone software products include StrandNGS, the scRNA Portal, and the PQRS polygenic risk score platform.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Over 5,400 protein biomarkers measurable from 2 microlitres of blood
+2 more records
Product overview1 text field

Strand Life Sciences operates as a multiomics solutions provider offering a portfolio of products and services that span the genomics and proteomics continuum. The core offerings include Pharma and Biomarker Discovery applications for drug target identification and translational research; High-Throughput Proteomics powered by the Olink Explore HT platform enabling analysis of over 5,400 protein biomarkers; and Diagnostics services combining PCR and NGS technologies for clinical molecular testing. Supporting the platform are software products including scRNA Portal for single-cell RNA analysis, PQRS for polygenic risk scoring, and StrandNGS for sequencing data analysis. Additional capabilities encompass Agricultural Technology solutions for plant genomics, Genomics Software Application Development for regulatory-compliant platforms, Compliance and Validation Services, Real-World Data Analysis for precision insights, and Biodiversity Informatics for social impact. The company also provides AI enablement capabilities including AI-Assisted Variant Interpretation, Data Organization and Therapeutic Applications of AI, and AI Guardrails, all built on a foundation of 25+ years of domain experience with over 300 specialists.

Product and service11 records
1StrandNGS
CategoryGenomics Analysis Software
Description

Next-generation sequencing data analysis software for visualization, statistical analysis, and biological interpretation of omics data, used by genomics researchers and clinical labs.

2scRNA Portal
CategoryBioinformatics Software
Description

A portal for single-cell RNA sequencing data curation and analysis, enabling researchers to manage and analyze scRNA-seq data.

3PQRS (Polygenic Risk Score)
CategoryRisk Prediction Software
Description

Polygenic Risk Score platform for predicting disease risk based on genomic variations and multi-omics data integration, targeted at clinical and research customers.

4Pharma and Biomarker Discovery Applications
CategoryResearch Services
Description

Service enabling pharmaceutical companies to identify drug targets and biomarkers through integrated multi-omics data analysis, translational research, and clinical studies across therapeutic areas.

5High-Throughput Proteomics Service
CategoryLaboratory Services
Description

Proteomics service powered by the Olink Explore HT platform, enabling measurement of over 5,400 protein biomarkers from 2 microlitres of blood for multi-omics research and drug discovery. Targeted at pharmaceutical and biotechnology research customers.

6NGS and PCR Diagnostics Applications
CategoryDiagnostic Services
Description

Clinical NGS and PCR diagnostic services for somatic and germline variant interpretation and oncology panel reporting, targeted at molecular diagnostics companies and clinical laboratories.

7Agricultural Technology Solutions
CategoryAgricultural Genomics Services
Description

Genomics solutions for plant and agricultural research, decoding plant omics for breeding and trait discovery applications.

8Genomics Software Application Development
CategorySoftware Services
Description

Custom software development services for omics data management and analysis, including HIPAA- and FDA-compliant platforms for medical devices and genomics tests. Targeted at US diagnostic and medical device companies.

9Compliance and Validation Services
CategoryRegulatory Services
Description

Regulatory compliance and validation services supporting clinical genomics and medical device software development, including FDA and HIPAA compliance requirements.

10Real-World Data Analysis
CategoryData Analytics Services
Description

Real-world patient data analytics combining clinical and omics datasets to deliver precision insights for pharmaceutical and healthcare customers.

11Biodiversity Informatics for Social Good
CategoryBioinformatics Services
Description

Biodiversity informatics venture applying Strand's omics platforms to conservation and social impact research use cases.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2026-01-01
Description

Deployment of Olink Explore HT platform for South Asia's first large-scale proteomics service. Enables measurement of 5,400+ protein biomarkers for multi-omics research and drug discovery.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-11-01
Description

Launched subsidized biomarker testing initiative for acute myeloid leukaemia (AML) and cholangiocarcinoma (CCA) across India. Government sector tests offered free, private sector costs significantly reduced. Aims to improve access to molecular diagnostics for underserved populations.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-11-01
Description

Tri-partite partnership with Servier India and MedGenome for cancer biomarker testing. Strand provides genomics expertise and testing capabilities for AML and cholangiocarcinoma diagnostics in India.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2024-06-01
Description

Strategic partnership announced June 2024 to accelerate integration of AI platforms across the biotechnology sector. Combines SOPHiA GENETICS' AI capabilities with Strand's multi-omics expertise for enhanced biomarker discovery and clinical research.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
1PierianDx (now Velsera)
TypeDirect peer
Description

Velsera (formerly PierianDx) provides clinical genomics interpretation and reporting software, comparable to Strand's clinical NGS pipeline for US diagnostic and device companies.

TypeDirect peer
Description

SOPHiA GENETICS operates a universal AI platform for genomics and radiomics, directly comparable to Strand's StrandOmics and AI-assisted variant interpretation. It is both a partner and a competitor in clinical multi-omics interpretation for global pharma and diagnostics labs.

TypeDirect peer
Description

Congenica delivers clinical genomics interpretation and rare disease diagnostics software, similar to Strand's clinical NGS reporting and variant interpretation capabilities for diagnostic labs.

TypeDirect peer
Description

Fabric Genomics provides AI-driven clinical NGS interpretation for hereditary disease and oncology, comparable to Strand's AI-Assisted Variant Interpretation and StrandOmics offerings for clinical reporting laboratories.

TypeBroad incumbent
Description

QIAGEN offers clinical genomics interpretation (QCI), sample technologies, and bioinformatics for pharma and molecular diagnostics. Comparable to Strand across both software products (StrandNGS vs. QCI) and pharma biomarker services.

TypeDirect peer
Description

MedGenome is an India- and US-based genomics diagnostics and research services company offering NGS-based clinical testing, biomarker discovery, and population genomics. It is a direct Strand peer in Indian clinical genomics and a co-partner in the Servier AML/CCA initiative.

TypeDirect peer
Description

DNAnexus provides a cloud-based genomics and biomedical data analysis platform with AI capabilities. Directly comparable to Strand's TileDB-integrated data architecture and multi-omics software platform ambitions for pharma R&D.

TypeOthers
Description

Olink provides the proteomics platform (Explore HT) that Strand deploys as South Asia's first service. While a partner rather than competitor, Olink's roadmap and pricing directly shape Strand's proteomics services economics.

TypeEmerging player
Description

GenomOncology provides precision oncology workflow software for NGS-based somatic variant interpretation and clinical reporting — directly comparable to StrandOmics oncology panel reporting.

TypeBroad incumbent
Description

Illumina is the dominant NGS instrument and secondary/tertiary analysis platform provider (DRAGEN, BaseSpace). While primarily an instrument vendor, its bioinformatics suite competes with Strand's interpretation capabilities, and Illumina is both a Strand customer and a powerful channel partner.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers6 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile5 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability10 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature8 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Strand Life Sciences

Genomic Diagnostics & Bioinformatics Servicesstrandls.com

Strand Life Sciences is a Bangalore-based, Reliance Industries-backed multi-omics company providing AI-driven genomics, proteomics, and clinical diagnostics software and lab services to global pharmaceutical firms, US diagnostic companies, and the Indian healthcare system, with a strategic push toward affordable consumer genomic testing.

What Strand Life Sciences does

Strand Life Sciences is a Bangalore-based, multi-omics solutions provider founded in 2000, operating as a subsidiary of Reliance Industries Limited. The company delivers an integrated platform spanning genomics, proteomics, transcriptomics, and spatial transcriptomics, with a portfolio of proprietary products including StrandNGS (NGS analysis software), PQRS (polygenic risk scoring), the scRNA Portal (single-cell RNA curation), and the StrandOmics clinical pipeline. Its technology stack combines AI-assisted variant interpretation, agentic AI for biomedical data curation, and a TileDB-integrated data architecture, supported by a CAP-accredited laboratory in India, HIPAA-compliant operations, and ISO 27001 certification.

Strand serves a hybrid customer base: global pharmaceutical and biotechnology enterprises seeking integrated multi-omics discovery, translational research, and biomarker validation programs (especially across India, South Asia, and West Asia); molecular diagnostics companies and US diagnostic/device firms requiring AI-driven somatic and germline variant interpretation, oncology panel reporting, and regulatory-compliant software; and, increasingly, the Indian healthcare system through affordable cancer screening and rare disease diagnostics. Strategic relationships include SOPHiA GENETICS (AI integration), Olink (high-throughput proteomics), TileDB (data infrastructure), and a tri-partite cancer biomarker testing program with Servier India and MedGenome.

The business model is predominantly professional services and B2B enterprise sales, with revenue generated from pharma biomarker discovery engagements, CAP-accredited lab services, software development for FDA/HIPAA-compliant omics platforms, and partnership-driven subsidized testing in India. Distribution leverages direct enterprise sales for global clients and the Reliance distribution network for consumer diagnostics in India, with a long-term strategic objective of reducing genomic test pricing to sub-Rs 1,000 to drive mass adoption similar to the Jio telecom disruption model.

Strand Life Sciences firmographics

Firmographics
Name
Strand Life Sciences
Legal name
Strand Life Sciences
Website
https://strandls.com
Company type
Private
Founded year
2000
Operating status
Operating
Headcount range
501–1,000 employees
Short description
Strand Life Sciences is a Bangalore-based, Reliance Industries-backed multi-omics company providing AI-driven genomics, proteomics, and clinical diagnostics software and lab services to global pharmaceutical firms, US diagnostic companies, and the Indian healthcare system, with a strategic push toward affordable consumer genomic testing.
Ownership category
akta.pro rank

Strand Life Sciences industry classification

Industry
Product category
Genomic Diagnostics & Bioinformatics Services
NAICS
Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Software Publishers (5132)
SIC
Services-Commercial Physical & Biological Research (8731), In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAGANAI
Bioinformatics, Multi-Omics Data Analysis & Interpretation Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
SECONDARYHLAGAJAD
Bioinformatics & Multi-omics Analysis Software
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAGANAE
Transcriptomics & Gene Expression Profiling Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
SECONDARYHLAAAMAJ
Genomic & Multi-Omic Biomarkers (NGS panels, transcriptomics, proteomics, metabolomics)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics

Keywords

  • Multi-omics bioinformatics
  • Clinical genomic diagnostics
  • Pharma biomarker discovery
  • NGS data analysis
  • AI variant interpretation

Where Strand Life Sciences is headquartered

Location

Headquarters

HQ city
Bangalore
HQ country
India
HQ region
Asia

Offices4 records

Markets served

Strand Life Sciences business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

  1. Genomic Diagnostics Services: B2B services providing NGS and PCR diagnostics, biomarker testing, and clinical reporting to pharmaceutical companies, biotechnology organisations, and diagnostic laboratories.
  2. Pharma and Biomarker Discovery: Clinical data and bioinformatics solutions for pharmaceutical companies for target discovery, translational research, and clinical research.
  3. Software Development Services: Omics software development for managing and analyzing data, including HIPAA- and FDA-compliant software for medical devices and genomics tests.
  4. CAP-Accredited Laboratory Services: Data generation services including single-cell, spatial transcriptomics and genomics from clinical samples in India-based CAP accredited laboratory.

Pricing tiers

ModelBillingPrice
Unit PricingOne time/ perpetual licenseCancerSpot cancer screening tests targeted at Rs 999

Go-to-market motion3 records

Distribution channels4 records

Marketing channels6 records

Strand Life Sciences product offering

Product offering

Core offering

Strand Life Sciences provides integrated multi-omics solutions combining genomics, proteomics, transcriptomics, and spatial transcriptomics with AI-driven bioinformatics for pharmaceutical, biotechnology, and diagnostic customers. Core offerings include Pharma and Biomarker Discovery, High-Throughput Proteomics using the Olink Explore HT platform, NGS and PCR clinical diagnostics, software application development, and compliance services. Standalone software products include StrandNGS, the scRNA Portal, and the PQRS polygenic risk score platform.

Product overview

Strand Life Sciences operates as a multiomics solutions provider offering a portfolio of products and services that span the genomics and proteomics continuum. The core offerings include Pharma and Biomarker Discovery applications for drug target identification and translational research; High-Throughput Proteomics powered by the Olink Explore HT platform enabling analysis of over 5,400 protein biomarkers; and Diagnostics services combining PCR and NGS technologies for clinical molecular testing. Supporting the platform are software products including scRNA Portal for single-cell RNA analysis, PQRS for polygenic risk scoring, and StrandNGS for sequencing data analysis. Additional capabilities encompass Agricultural Technology solutions for plant genomics, Genomics Software Application Development for regulatory-compliant platforms, Compliance and Validation Services, Real-World Data Analysis for precision insights, and Biodiversity Informatics for social impact. The company also provides AI enablement capabilities including AI-Assisted Variant Interpretation, Data Organization and Therapeutic Applications of AI, and AI Guardrails, all built on a foundation of 25+ years of domain experience with over 300 specialists.

Differentiator

Problem solved

Functional benefit

Brands

  • scRNA Portal: Portal for single-cell RNA curation and analysis
  • PQRS
  • StrandNGS
  • CancerSpot

Products and services

  • StrandNGS Next-generation sequencing data analysis software for visualization, statistical analysis, and biological interpretation of omics data, used by genomics researchers and clinical labs.
  • scRNA Portal A portal for single-cell RNA sequencing data curation and analysis, enabling researchers to manage and analyze scRNA-seq data.
  • PQRS (Polygenic Risk Score) Polygenic Risk Score platform for predicting disease risk based on genomic variations and multi-omics data integration, targeted at clinical and research customers.
  • Pharma and Biomarker Discovery Applications Service enabling pharmaceutical companies to identify drug targets and biomarkers through integrated multi-omics data analysis, translational research, and clinical studies across therapeutic areas.
  • High-Throughput Proteomics Service Proteomics service powered by the Olink Explore HT platform, enabling measurement of over 5,400 protein biomarkers from 2 microlitres of blood for multi-omics research and drug discovery. Targeted at pharmaceutical and biotechnology research customers.
  • NGS and PCR Diagnostics Applications Clinical NGS and PCR diagnostic services for somatic and germline variant interpretation and oncology panel reporting, targeted at molecular diagnostics companies and clinical laboratories.
  • Agricultural Technology Solutions Genomics solutions for plant and agricultural research, decoding plant omics for breeding and trait discovery applications.
  • Genomics Software Application Development Custom software development services for omics data management and analysis, including HIPAA- and FDA-compliant platforms for medical devices and genomics tests. Targeted at US diagnostic and medical device companies.
  • Compliance and Validation Services Regulatory compliance and validation services supporting clinical genomics and medical device software development, including FDA and HIPAA compliance requirements.
  • Real-World Data Analysis Real-world patient data analytics combining clinical and omics datasets to deliver precision insights for pharmaceutical and healthcare customers.
  • Biodiversity Informatics for Social Good Biodiversity informatics venture applying Strand's omics platforms to conservation and social impact research use cases.

Quantifiable outcome

  • Over 5,400 protein biomarkers measurable from 2 microlitres of blood
  • +2 more outcomes

Companies that use Strand Life Sciences

Customer profile

Named customers6 records

Segments5 records

Ideal customer profiles5 records

Strand Life Sciences technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability10 records

Feature8 records

Strand Life Sciences partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core.

  • OlinkcoreTechnology or Integration · 1 January 2026Deployment of Olink Explore HT platform for South Asia's first large-scale proteomics service. Enables measurement of 5,400+ protein biomarkers for multi-omics research and drug discovery.
  • Servier IndiacoreStrategic or Co-development Partner · 1 November 2025Launched subsidized biomarker testing initiative for acute myeloid leukaemia (AML) and cholangiocarcinoma (CCA) across India. Government sector tests offered free, private sector costs significantly reduced. Aims to improve access to molecular diagnostics for underserved populations.
  • MedGenomecoreStrategic or Co-development Partner · 1 November 2025Tri-partite partnership with Servier India and MedGenome for cancer biomarker testing. Strand provides genomics expertise and testing capabilities for AML and cholangiocarcinoma diagnostics in India.
  • SOPHiA GENETICScoreTechnology or Integration · 1 June 2024Strategic partnership announced June 2024 to accelerate integration of AI platforms across the biotechnology sector. Combines SOPHiA GENETICS' AI capabilities with Strand's multi-omics expertise for enhanced biomarker discovery and clinical research.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Strand Life Sciences competitors and assessment

Company assessment

Direct peers

  • PierianDx (now Velsera): Velsera (formerly PierianDx) provides clinical genomics interpretation and reporting software, comparable to Strand's clinical NGS pipeline for US diagnostic and device companies.
  • SOPHiA GENETICS: SOPHiA GENETICS operates a universal AI platform for genomics and radiomics, directly comparable to Strand's StrandOmics and AI-assisted variant interpretation. It is both a partner and a competitor in clinical multi-omics interpretation for global pharma and diagnostics labs.
  • Congenica: Congenica delivers clinical genomics interpretation and rare disease diagnostics software, similar to Strand's clinical NGS reporting and variant interpretation capabilities for diagnostic labs.
  • Fabric Genomics: Fabric Genomics provides AI-driven clinical NGS interpretation for hereditary disease and oncology, comparable to Strand's AI-Assisted Variant Interpretation and StrandOmics offerings for clinical reporting laboratories.
  • MedGenome: MedGenome is an India- and US-based genomics diagnostics and research services company offering NGS-based clinical testing, biomarker discovery, and population genomics. It is a direct Strand peer in Indian clinical genomics and a co-partner in the Servier AML/CCA initiative.
  • DNAnexus: DNAnexus provides a cloud-based genomics and biomedical data analysis platform with AI capabilities. Directly comparable to Strand's TileDB-integrated data architecture and multi-omics software platform ambitions for pharma R&D.

Broad incumbents

  • QIAGEN Digital Insights (formerly Qiagen Bioinformatics): QIAGEN offers clinical genomics interpretation (QCI), sample technologies, and bioinformatics for pharma and molecular diagnostics. Comparable to Strand across both software products (StrandNGS vs. QCI) and pharma biomarker services.
  • Illumina (DRAGEN / BaseSpace): Illumina is the dominant NGS instrument and secondary/tertiary analysis platform provider (DRAGEN, BaseSpace). While primarily an instrument vendor, its bioinformatics suite competes with Strand's interpretation capabilities, and Illumina is both a Strand customer and a powerful channel partner.

Others

  • Olink Holding AB: Olink provides the proteomics platform (Explore HT) that Strand deploys as South Asia's first service. While a partner rather than competitor, Olink's roadmap and pricing directly shape Strand's proteomics services economics.

Emerging players

  • GenomOncology: GenomOncology provides precision oncology workflow software for NGS-based somatic variant interpretation and clinical reporting — directly comparable to StrandOmics oncology panel reporting.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Strand Life Sciences social profiles

Digital presence

Strand Life Sciences compliance and trust

Trust signal

Compliance3 records

Strand Life Sciences financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Strand Life Sciences leadership team

Management profile

Number of profiles

Profiles4 records

Strand Life Sciences funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Strand Life Sciences M&A and investment

M&A and investment

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Strand Life Sciences

What does Strand Life Sciences do?

Strand Life Sciences provides integrated multi-omics solutions combining genomics, proteomics, transcriptomics, and spatial transcriptomics with AI-driven bioinformatics for pharmaceutical, biotechnology, and diagnostic customers. Core offerings include Pharma and Biomarker Discovery, High-Throughput Proteomics using the Olink Explore HT platform, NGS and PCR clinical diagnostics, software application development, and compliance services. Standalone software products include StrandNGS, the scRNA Portal, and the PQRS polygenic risk score platform.

Is Strand Life Sciences a public or private company?

Strand Life Sciences is a private company. It is classified as corporate owned and is currently operating.

When was Strand Life Sciences founded?

Strand Life Sciences was founded in 2000. It employs 501 to 1,000 people.

Where is Strand Life Sciences based?

Strand Life Sciences is headquartered in Bangalore, India, in the Asia region.

How does Strand Life Sciences make money?

Four revenue lines are on record. Genomic Diagnostics Services are the primary driver. The others are pharma and Biomarker Discovery, software Development Services and CAP-Accredited Laboratory Services.

Who are Strand Life Sciences's main competitors?

Direct peers on record are PierianDx (now Velsera), SOPHiA GENETICS, Congenica, Fabric Genomics, MedGenome and DNAnexus. Broad incumbents are QIAGEN Digital Insights (formerly Qiagen Bioinformatics) and Illumina (DRAGEN / BaseSpace). Olink Holding AB is listed as an others. GenomOncology is listed as an emerging player.

Does Strand Life Sciences have an API?

No public API is recorded for Strand Life Sciences.

What industry is Strand Life Sciences in?

Strand Life Sciences's product category is Genomic Diagnostics & Bioinformatics Services. Its primary akta.pro industry code is HLAGANAI, Bioinformatics, Multi-Omics Data Analysis & Interpretation Services, with a secondary code of HLAGAJAD, Bioinformatics & Multi-omics Analysis Software. Its NAICS code is 5417 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
The HinduPan-Indian study finds that higher levels of DNA fragments in blood strengthen cancer signalsA blood test called CancerSpot, developed by Strand Life Sciences, detected 72% of cancer cases in a study of 1,480 participants across 43 hospitals. The test had a 1.4% false-positive rate and examined 14 cancer types. Researchers found higher circulating DNA levels strengthened cancer signals, challenging prior assumptions.Digital Health NewsAstraZeneca Pharma India & Strand Life Sciences to Explore Healthcare CollaborationAstraZeneca Pharma India signed a Letter of Intent with Strand Life Sciences, a Reliance Industries subsidiary, to explore healthcare collaboration in India. The partnership aims to address barriers to timely cancer diagnosis through precision diagnostics and personalized treatment, combining AstraZeneca's oncology expertise with Strand's genomics capabilities.Financial ExpressAstraZeneca Pharma India partners with Reliance Industries' subsidiary Strand Life SciencesAstraZeneca Pharma India signed a Letter of Intent with Strand Life Sciences, a Reliance Industries subsidiary, to explore healthcare collaboration in India. The move aims to improve cancer diagnosis and treatment, with the companies not related parties and the LOI not a related-party transaction.CNBCTV18AstraZeneca Pharma India signs LoI with Reliance's Strand Life Sciences for healthcare tie-up - CNBC TV18AstraZeneca Pharma India signed a letter of intent with Reliance's Strand Life Sciences to explore healthcare collaboration in India. The announcement sent shares up 2.4% to ₹6,175.5, and the company reported a 14.9% year-on-year net profit increase to ₹62.3 crore for Q2 FY27.Deccan ChronicleAP To Offer Free Genetic Tests for Cancer PatientsAndhra Pradesh will offer free genetic testing for cancer patients at a new laboratory at Guntur Government General Hospital, inaugurated September 22. The Rs 2.5 crore facility, built with AstraZeneca and Strand Life Sciences, will test breast and lung cancer samples, with AstraZeneca covering costs for 1,000 patients each. A state-level centre is proposed for Amaravati.The HinduAdvanced cancer genetic testing facility to open in Guntur on Sept. 22A specialized genetic testing laboratory will open at the Government General Hospital in Guntur on September 22, jointly by the Andhra Pradesh government, AstraZeneca, and Strand Life Sciences. The ₹2.5 crore facility will initially test breast and lung cancer patients, with AstraZeneca covering costs and 2,000 samples planned over two years. A full-scale state-level centre is proposed for Amaravati.openPR.comCompetitive Landscape: Key Market Leaders and New Entrants in the Somatic Genetic Testing SectorThe Business Research Company released a market report projecting the somatic genetic testing sector will reach $14.92 billion by 2030, driven by next-generation sequencing and precision medicine adoption. The article highlights strategic activities including Genomenon Inc.'s acquisition of Boston Genetics Inc. to enhance genomic interpretation capabilities and Strand Life Sciences' launch of a new liquid biopsy test in India.Medical BuyerAndhra inks MoU with AstraZeneca to establish genomic solutions centreThe Andhra Pradesh government signed an MoU with AstraZeneca India to establish an Integrated Genomics Solution Centre in Amaravati, focused on precision oncology care using advanced genetic sequencing and biomarker testing for lung and breast cancer. The facility, to be developed in collaboration with Strand Life Sciences and Qure.ai, will deploy Next-Generation Sequencing and AI tools for early cancer detection and customized treatment protocols. AI-enabled X-ray screening systems will also be installed in government hospitals across the state as part of the initiative.The Hans IndiaPrecision oncology move to put Amaravati on India's genomics mapAndhra Pradesh's Health Department and AstraZeneca India signed an MoU to establish an Integrated Genomics Solutions Center in Amaravati, marking India's first integrated precision oncology initiative. The project, with Strand Life Sciences and Qure.ai, will use NGS, AI, and diagnostics for lung and breast cancer, deploying AI-powered chest X-ray systems for early detection.The Hans IndiaPrecision oncology move to put Amaravati on India's genomics mapAndhra Pradesh's government partnered with AstraZeneca India to establish an Integrated Genomics Solutions Center in Amaravati, aiming to advance precision oncology and cancer care in India. The initiative includes collaboration with Strand Life Sciences and Qure.ai, focusing on personalized treatment for lung and breast cancer using genomics, AI, and advanced diagnostics.